Author

Angela De Michele

Observed names: Angela DeMichele, Angela M. De Michele, DeMichele, Angela

Institution: University of Pennsylvania

Observed institutions: Yeshiva University, University of Pennsylvania

OpenAlex ID: A5113780385

Prognostic correlations with the microbiome of breast cancer subtypes

2021 · Sagarika Banerjee, Zhi Wei, et al. · Cell Death and Disease · 118

Modifiable Risk Factors for Breast Cancer Recurrence: What Can We Tell Survivors?

2007 · Sandra A. Norman, Sheryl L. Potashnik, et al. · Journal of Women s Health · 34

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)

2011 · I-SPY TRIAL Investigators, Cheryl Lin, et al. · Breast Cancer Research and Treatment · 31

Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

2025 · Rita A. Mukhtar, Katrina Dimitroff, et al. · Annals of Surgical Oncology · 10

Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial).

2025 · Natasha Hunter, Heather Anne Parsons, et al. · Journal of Clinical Oncology · 10

Abstract 859: Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer

2016 · Denise M. Wolf, Christina Yau, et al. · Cancer Research · 7

Childhood ALL and second neoplasms

2007 · Tapan N. Maniar, Inbal Braunstein, et al. · Cancer Biology & Therapy · 6

Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

2025 · Julie Van Hassel, Katrina Dimitroff, et al. · Annals of Surgical Oncology · 3

Abstract PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study

2025 · Eleanor Taranto, Nicholas J. Seewald, et al. · Clinical Cancer Research · 2

Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL

2016 · Denise M. Wolf, Christina Yau, et al. · Cancer Research · 2

DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer

2025 · Elizabeth M. Chislock, Tien-chi Pan, et al. · npj Breast Cancer · 1

ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

2025 · Julie Van Hassel, Katrina Dimitroff, et al. · Annals of Surgical Oncology

ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

2025 · Rita A. Mukhtar, Katrina Dimitroff, et al. · Annals of Surgical Oncology

Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.

2025 · Amrita Basu, Saumya Umashankar, et al. · Journal of Clinical Oncology

Works count: 15

Citation count: 224

H-index: 6

I10-index: 5